Valuation: Nectar Lifesciences Limited

Market Cap 2.08B 21.68M 19.13M 18.1M 16.42M 30.78M 31.09M 217M 83.7M 1.06B 81.42M 79.64M 3.42B P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 829M 8.64M 7.63M 7.22M 6.55M 12.27M 12.39M 86.59M 33.37M 424M 32.46M 31.75M 1.36B EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.34%
Yield 2025 *
-
Yield 2026 -
1 day-0.09%
1 week-2.01%
Current month-14.59%
1 month-14.11%
3 months-6.22%
6 months+9.51%
Current year-44.82%
1 week 10.56
Extreme 10.56
11.2
1 month 10.56
Extreme 10.56
12.93
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 13/11/2022
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 26/06/1995
Director/Board Member 69 10/02/2019
Director/Board Member 75 20/09/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/12/24 Buy 400,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%-2.01%-25.73%-57.33% 21.69M
+1.47%-0.21%+17.54%+64.71% 45.94B
+2.89%+2.52%+46.81%+113.64% 36.98B
-1.19%+3.40%+23.13%+99.17% 12.63B
-0.32%-0.49%-8.01%+18.49% 11.65B
-0.19%0.00%+17.65%+137.44% 8.97B
-1.52%-2.32%+35.43%-18.92% 7.19B
-0.56%-2.14%+26.79%+38.31% 7B
+4.98%-0.35%+23.83%+214.24% 6.84B
+0.30%-4.59%-50.63%+1.01% 4.93B
Average +0.56%-1.15%+10.68%+61.08% 14.21B
Weighted average by Cap. +1.22%-0.76%+22.86%+80.74%

Financials

2025 2026
Net sales 16.7B 174M 154M 145M 132M 247M 250M 1.74B 672M 8.53B 654M 639M 27.45B -
Net income -1.14B -11.85M -10.46M -9.89M -8.97M -16.82M -16.99M -119M -45.74M -581M -44.49M -43.52M -1.87B -2.93B -30.52M -26.94M -25.49M -23.11M -43.33M -43.76M -306M -118M -1.5B -115M -112M -4.81B
Net Debt 5.62B 58.6M 51.71M 48.93M 44.37M 83.19M 84.01M 587M 226M 2.87B 220M 215M 9.24B -1.25B -13.04M -11.51M -10.89M -9.87M -18.51M -18.69M -131M -50.33M -639M -48.96M -47.89M -2.06B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
29/09/26 ₹10.71 -0.09% 93,379
28/09/26 ₹10.72 -1.11% 76,851
25/09/26 ₹10.84 -0.37% 103,563
24/09/26 ₹10.88 -1.63% 94,617
23/09/26 ₹11.06 +2.12% 92,820
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock